Increased long-term mortality after survival of invasive pneumococcal disease: a population-based study

References

• Ortqvist A, Sterner G, Nilsson JA. Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis. 1985;17:377–386.
   PubMedGoogle Scholar
• Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med. 2005;26:563–574.
   PubMed Web of Science ®Google Scholar
• Steens A, Eriksen HM, Blystad H. What are the most important infectious diseases among those ≥65 years: a comprehensive analysis on notifiable diseases, Norway, 1993–2011. BMC Infect Dis. 2014;14:57.
   PubMed Web of Science ®Google Scholar
• Sjostrom K, Spindler C, Ortqvist A, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis. 2006;42:451–459.
   PubMed Web of Science ®Google Scholar
• Winters BD, Eberlein M, Leung J, et al. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med. 2010;38:1276–1283.
   PubMed Web of Science ®Google Scholar
• Wang HE, Szychowski JM, Griffin R, Safford MM, Shapiro NI, Howard G. Long-term mortality after community-acquired sepsis: a longitudinal population-based cohort study. BMJ Open. 2014;4:e004283.
   Web of Science ®Google Scholar
• Alanee SR, McGee L, Jackson D, et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis. 2007;45:46–51.
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009;6:e1000081.
   PubMed Web of Science ®Google Scholar
• Ricketson LJ, Nettel-Aguirre A, Vanderkooi OG, et al. Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance study. PLOS One. 2013;8:e71924.
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65:17–24.
   PubMed Web of Science ®Google Scholar
• Sandvall B, Rueda AM, Musher DM. Long-term survival following pneumococcal pneumonia. Clin Infect Dis. 2013;56:1145–1146.
   PubMed Web of Science ®Google Scholar
• Vestrheim DF, Lovoll O, Aaberge IS, et al. Effectiveness of a 2 + 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine. 2008;26:3277–3281.
   PubMed Web of Science ®Google Scholar
• Vestrheim DF, Hoiby EA, Bergsaker MR, et al. Indirect effect of conjugate pneumococcal vaccination in a 2 + 1 dose schedule. Vaccine. 2010;28:2214–2221.
   PubMed Web of Science ®Google Scholar
• Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31:6232–6238.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–309.
   PubMed Web of Science ®Google Scholar
• Steens A, Vestrheim DF, de Blasio BF. Pneumococcal vaccination in older adults in the era of childhood vaccination: public health insights from a Norwegian statistical prediction study. Epidemics. 2015;11:24–31.
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Rose CE, Jr, Fry AM, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–386.
   PubMed Web of Science ®Google Scholar
• Cruickshank HC, Jefferies JM, Clarke SC. Lifestyle risk factors for invasive pneumococcal disease: a systematic review. BMJ Open. 2014;4:e005224.
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 2000;342:681–689.
   PubMed Web of Science ®Google Scholar
• van Kruijsdijk RC, van der Graaf Y, Koffijberg H, et al. Cause-specific mortality and years of life lost in patients with different manifestations of vascular disease. Eur J Prev Cardiol. 2016;23:160–169.
   PubMed Web of Science ®Google Scholar
• Roper NA, Bilous RW, Kelly WF, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ. 2001;322:1389–1393.
   PubMed Web of Science ®Google Scholar
• Haraldsen P, Andersson R. Quality of life, morbidity, and mortality after surgical intensive care: a follow-up study of patients treated for abdominal sepsis in the surgical intensive care unit. Eur J Surg Suppl. 2003;588:23–27.
   Google Scholar
• Karlsson S, Ruokonen E, Varpula T, et al. Long-term outcome and quality-adjusted life years after severe sepsis. Crit Care Med. 2009;37:1268–1274.
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Andrews N, Waight PA, et al. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One. 2012;7:e39150.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis. 2010;51:692–699.
   PubMed Web of Science ®Google Scholar
• Browall S, Backhaus E, Naucler P, et al. Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types. Eur Respir J. 2014;44:1646–1657.
   PubMed Web of Science ®Google Scholar